Institute of Medical Technology, Peking University Health Science Center, Beijing 100000, China.
Department of Radiation Oncology, Peking University 3rd Hospital, Beijing 100191, China.
Curr Oncol. 2021 Nov 9;28(6):4577-4586. doi: 10.3390/curroncol28060387.
Cervical cancer is the fourth most common cancer in females worldwide. Patients with stage III and IV cervical cancer based on the Federation of Gynecology and Obstetrics (FIGO) classification have higher recurrence rates. Because of organs at risk (OAR) protection and the low indication rate of salvage surgery, the choice of treatment is always challenging. Systemic chemotherapy is palliative and can be performed in conjunction with surgery or radiotherapy; however, it has no significant benefit to survival. Brachytherapy and stereotactic body radiotherapy (SBRT) are characterized by extremely high radiation doses applied to tumor cells while sparing the normal tissues. Several studies have investigated the efficacy of these technologies in recurrent cervical cancer and showed promising results. The immune checkpoint inhibitors approach was also investigated and showed promising results too. Herein, we report a case of a patient with cervical cancer that recurred five months after adjuvant chemotherapy and concurrent chemoradiotherapy. The disease prognosis after interstitial implantation brachytherapy (IIB) was determined. Then, the patient underwent radioactive 125I-seed implantation combined with PD-1 inhibitor treatment. The patient exhibited a partial response after seed implantation, and up to now, the duration of this partial response was 24 months.
宫颈癌是全球女性中第四常见的癌症。根据妇产科联合会（FIGO）分类，III 期和 IV 期宫颈癌患者的复发率较高。由于保护危险器官（OAR）和挽救性手术的低指征率，治疗的选择总是具有挑战性。全身化疗是姑息性的，可以与手术或放疗联合进行；然而，它对生存没有显著益处。近距离放疗和立体定向体部放疗（SBRT）的特点是将极高的辐射剂量应用于肿瘤细胞，同时保护正常组织。一些研究已经探讨了这些技术在复发性宫颈癌中的疗效，并显示出有希望的结果。免疫检查点抑制剂的方法也进行了研究，也显示出了有希望的结果。在此，我们报告了一例宫颈癌患者，在辅助化疗和同期放化疗后 5 个月复发。通过间质内植入近距离放疗（IIB）来确定疾病的预后。然后，患者接受放射性 125I 种子植入联合 PD-1 抑制剂治疗。患者在种子植入后出现部分缓解，到目前为止，部分缓解的持续时间为 24 个月。
